Veracyte Ramps up Clinical Evidence Generation, Driving Gains in Prostate and Thyroid Test Business
The company reported significant revenue growth for Q4 2022, which it attributed to its success in driving clinical test adoption.
UnitedHealthcare Issues New Policy Expanding Coverage of Precision Oncology Diagnostics
The private payor added new coverage criteria for sequencing tests in approved companion diagnostic indications, as well as prostate cancer risk assays.
360Dx Top 30 Grows 8 Percent, Continues Upward Climb
Of the 30 companies in the index, 21 saw their stock prices rise, while nine firms' share prices decreased.
Veracyte Reports 25 Percent Q3 Revenue Growth, Raises Full-Year Guidance
The firm said that its Decipher and Afirma tests each benefited from expanded coverage and largely drove growth this quarter.
360Dx Top 30 Rises 2 Percent After Months of Decline
Of the 30 companies in the index, 22 saw their stock prices rise, while eight firms saw their share prices decrease.
Sep 1, 2022
360Dx Top 30 Tumbles in August
May 4, 2022
May 3, 2022
Veracyte Q1 Revenues Jump 85 Percent
Feb 28, 2022
Veracyte Revenues Almost Double in Q4
Nov 9, 2021
Veracyte Q3 Revenues Nearly Double
Oct 28, 2021
Jun 4, 2021
Jun 1, 2021
Veracyte to Acquire HalioDx for €260M
Feb 17, 2021